Brief: JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA
02/07/2026 18:12
BRIEF-JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA July 2 (Reuters) - Edding Genor Group Holdings Ltd 6998.HK:
PHASE IB/II CLINICAL TRIAL OF GB268 OBTAINS IND APPROVAL BY NMPA
Further company coverage: 6998.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edding Genor group
See all newsBrief: JHBP CY Says Chairman And CEO Ni Xin To Buy Shares Up To USD 1 Million From Aug 31, 2026
Brief: Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HY
Brief: Jhbp Cy Disposal Of Equity Interest In Candid Therapeutics
Edding Genor climbs on approval of clinical trial of cancer drug in China
Brief: JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA